SI1373259T1 - Pyridazinone aldose reductase inhibitors - Google Patents

Pyridazinone aldose reductase inhibitors

Info

Publication number: SI1373259T1
Authority: SI; Slovenia
Prior art keywords: reductase inhibitors; aldose reductase; pyridazinone aldose; pyridazinone; inhibitors
Prior art date: 2001-03-30

Application number

SI200230071T

Other languages

English (en)

Slovenian (sl)

Inventor

Banavara Lakshman Mylari

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2002-01-31

Publication date

2005-04-30

2002-01-31 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-04-30 Publication of SI1373259T1 publication Critical patent/SI1373259T1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SI200230071T 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors SI1373259T1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (fr)	2001-03-30	2002-01-31	Inhibiteurs pyridazinone d'aldose réductase
EP02716247A EP1373259B1 (fr)	2001-03-30	2002-01-31	Inhibiteurs pyridazinone d'aldose r ductase

Publications (1)

Publication Number	Publication Date
SI1373259T1 true SI1373259T1 (en)	2005-04-30

Family

ID=23071435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200230071T SI1373259T1 (en)	2001-03-30	2002-01-31	Pyridazinone aldose reductase inhibitors

Country Status (44)

Country	Link
US (2)	US6579879B2 (fr)
EP (3)	EP1491540B1 (fr)
JP (1)	JP2004528319A (fr)
KR (1)	KR100586138B1 (fr)
CN (1)	CN1215067C (fr)
AP (1)	AP2002002461A0 (fr)
AR (1)	AR035798A1 (fr)
AT (3)	ATE348100T1 (fr)
AU (1)	AU2002226634B2 (fr)
BG (1)	BG108179A (fr)
BR (1)	BR0208571A (fr)
CA (1)	CA2442476A1 (fr)
CZ (1)	CZ20032563A3 (fr)
DE (3)	DE60216823T2 (fr)
DK (2)	DK1491540T3 (fr)
EA (1)	EA006023B1 (fr)
EC (1)	ECSP034671A (fr)
EE (1)	EE200300470A (fr)
ES (2)	ES2274369T3 (fr)
GE (1)	GEP20053675B (fr)
HK (1)	HK1061678A1 (fr)
HR (1)	HRP20030752A2 (fr)
HU (1)	HUP0303644A3 (fr)
IL (1)	IL156462A0 (fr)
IS (3)	IS2205B (fr)
MA (1)	MA27003A1 (fr)
MX (1)	MXPA03008850A (fr)
MY (1)	MY134304A (fr)
NO (1)	NO20034345L (fr)
NZ (1)	NZ528406A (fr)
OA (1)	OA12453A (fr)
PA (1)	PA8541801A1 (fr)
PE (1)	PE20030007A1 (fr)
PL (1)	PL365294A1 (fr)
PT (2)	PT1491540E (fr)
SI (1)	SI1373259T1 (fr)
SK (1)	SK11852003A3 (fr)
TN (1)	TNSN02037A1 (fr)
TW (1)	TWI245762B (fr)
UA (1)	UA73236C2 (fr)
UY (1)	UY27237A1 (fr)
WO (1)	WO2002079198A1 (fr)
YU (1)	YU71403A (fr)
ZA (1)	ZA200304671B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL126999A (en)	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
DE60204611T2 (de) *	2001-02-28	2006-05-11	Pfizer Products Inc., Groton	Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
JP2004528319A (ja) *	2001-03-30	2004-09-16	ファイザー・プロダクツ・インク	ピリダジノンアルドースレダクダーゼ阻害物質
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
RU2278116C2 (ru)	2002-01-09	2006-06-20	Пфайзер Продактс Инк.	Способ и промежуточные продукты для получения пиридазиноновых антидиабетических средств
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (fr) *	2004-06-30	2006-03-16	Whitehead Institute For Biomedical Research	Procedes pour analyse de site haut rendement au niveau du genome
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
AU2007206016A1 (en) *	2006-01-13	2007-07-26	Wyeth	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
RS53230B (en)	2006-06-27	2014-08-29	Takeda Pharmaceutical Company Limited	CONDENSED CYCLICAL UNITS AS GPR40 RECEPTOR MODULATORS
WO2008070496A2 (fr)	2006-12-01	2008-06-12	Bristol-Myers Squibb Company	Inhibiteurs d'amino cetp étendus
US8173645B2 (en) *	2007-03-21	2012-05-08	Takeda San Diego, Inc.	Glucokinase activators
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
WO2011071995A2 (fr)	2009-12-08	2011-06-16	Case Western Reserve University	Composés et procédés de traitement de troubles oculaires
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
AU2012308243B2 (en) *	2011-09-15	2017-09-14	Taipei Medical University	Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
RU2618628C1 (ru)	2013-04-17	2017-05-05	Пфайзер Инк.	Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
US20180118756A1 (en) *	2015-04-14	2018-05-03	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (fr)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	Nouvelles formes pharmaceutiques du sildénafil
SI3352754T1 (sl)	2016-06-21	2021-03-31	The Trustees Of Columbia University In The City Of New York	Zaviralci aldozne reduktaze in postopki njihove uporabe
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
US11690847B2 (en)	2016-11-30	2023-07-04	Case Western Reserve University	Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
PL3658142T3 (pl)	2017-07-28	2024-08-26	Applied Therapeutics, Inc.	Związki i sposoby leczenia galaktozemii
CA3125765A1 (fr)	2019-01-18	2020-07-23	Astrazeneca Ab	Inhibiteurs de pcsk9 et leurs procedes d'utilisation
CN113966396A (zh)	2019-05-07	2022-01-21	迈阿密大学	遗传性神经病和相关障碍的治疗和检测
MX2021014443A (es)	2019-05-31	2022-01-06	Ikena Oncology Inc	Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
BR112021024224A2 (pt)	2019-05-31	2022-04-26	Ikena Oncology Inc	Inibidores de tead e usos dos mesmos
WO2022120353A1 (fr) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (fr) *	1990-11-30	1992-06-11	Tsumura & Co.	Derive de benzopyrone et inhibiteur de reductase d'aldose contenant ce derive en tant qu'ingredient actif
EP0582643A1 (fr)	1991-03-28	1994-02-16	Pfizer Inc.	Acides acetiques de pyridazinone
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0003647A3 (en) *	1997-09-24	2002-12-28	Orion Corp	Bisethers of 1-oxa, aza and thianaphthalen-2-ones, their use for producing medicaments, the medicaments and their intermediates
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2004528319A (ja) *	2001-03-30	2004-09-16	ファイザー・プロダクツ・インク	ピリダジノンアルドースレダクダーゼ阻害物質
JP2004528344A (ja) *	2001-04-30	2004-09-16	ファイザー・プロダクツ・インク	アルドースレダクターゼ阻害薬とシクロオキシゲナーゼ−２阻害薬の併用
RU2278116C2 (ru) *	2002-01-09	2006-06-20	Пфайзер Продактс Инк.	Способ и промежуточные продукты для получения пиридазиноновых антидиабетических средств

2002
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/fr not_active Expired - Lifetime
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/fr active IP Right Grant
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 EP EP02716247A patent/EP1373259B1/fr not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 CA CA002442476A patent/CA2442476A1/fr not_active Abandoned
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 EP EP04023150A patent/EP1491541B1/fr not_active Expired - Lifetime
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown

Also Published As

Publication number	Publication date
CA2442476A1 (fr)	2002-10-10
DK1373259T3 (da)	2005-03-29
DE60217930T2 (de)	2007-10-18
DE60216823T2 (de)	2007-10-04
WO2002079198A1 (fr)	2002-10-10
US6579879B2 (en)	2003-06-17
ES2231681T3 (es)	2005-05-16
CN1500087A (zh)	2004-05-26
EA006023B1 (ru)	2005-08-25
IS6845A (is)	2003-06-16
AP2002002461A0 (en)	2002-06-30
ATE348100T1 (de)	2007-01-15
SK11852003A3 (sk)	2004-07-07
YU71403A (sh)	2006-05-25
TNSN02037A1 (fr)	2005-12-23
EA200300673A1 (ru)	2003-12-25
UA73236C2 (en)	2005-06-15
OA12453A (en)	2006-05-24
EP1373259B1 (fr)	2004-12-29
IS8251A (is)	2006-01-23
NO20034345D0 (no)	2003-09-29
EP1491541A1 (fr)	2004-12-29
ATE286049T1 (de)	2005-01-15
TWI245762B (en)	2005-12-21
IL156462A0 (en)	2004-01-04
EP1491541B1 (fr)	2007-01-24
DE60202452C5 (de)	2006-11-23
UY27237A1 (es)	2002-12-31
IS8250A (is)	2006-01-23
PE20030007A1 (es)	2003-01-28
US20030162784A1 (en)	2003-08-28
EP1491540A1 (fr)	2004-12-29
AU2002226634B2 (en)	2007-01-25
PT1373259E (pt)	2005-03-31
MY134304A (en)	2007-12-31
DE60202452T2 (de)	2006-02-09
AR035798A1 (es)	2004-07-14
ECSP034671A (es)	2003-08-29
KR100586138B1 (ko)	2006-06-07
PT1491540E (pt)	2007-01-31
BG108179A (en)	2004-09-30
HK1061678A1 (en)	2004-09-30
GEP20053675B (en)	2005-11-25
EE200300470A (et)	2004-02-16
BR0208571A (pt)	2004-03-23
DK1491540T3 (da)	2007-03-26
ES2274369T3 (es)	2007-05-16
US6849629B2 (en)	2005-02-01
EP1491540B1 (fr)	2006-12-13
JP2004528319A (ja)	2004-09-16
ZA200304671B (en)	2004-06-25
MA27003A1 (fr)	2004-12-20
DE60217930D1 (de)	2007-03-15
HUP0303644A2 (hu)	2004-03-01
MXPA03008850A (es)	2003-12-04
ATE352551T1 (de)	2007-02-15
PL365294A1 (en)	2004-12-27
KR20030088484A (ko)	2003-11-19
DE60202452D1 (de)	2005-02-03
NO20034345L (no)	2003-09-29
CZ20032563A3 (cs)	2004-05-12
DE60216823D1 (de)	2007-01-25
PA8541801A1 (es)	2002-10-28
HUP0303644A3 (en)	2008-06-30
HRP20030752A2 (en)	2005-06-30
EP1373259A1 (fr)	2004-01-02
IS2205B (is)	2007-02-15
NZ528406A (en)	2004-03-26
US20020143017A1 (en)	2002-10-03
CN1215067C (zh)	2005-08-17

Publication	Publication Date	Title
IL156462A0 (en)	2004-01-04	Pyridazinone aldose reductase inhibitors
AU2002250394A1 (en)	2002-10-08	Rho-kinase inhibitors
AU2002245709A1 (en)	2002-10-08	Rho-kinase inhibitors
AU2002357117A8 (en)	2003-06-30	Simplified eukaryotic nitrate reductase
PL363391A1 (en)	2004-11-15	Phthalayinone-piperidino-derivatives as pde4 inhibitors
GB2406009B (en)	2005-11-23	Amplifier
AU4217201A (en)	2001-10-03	Tri-aryl-substituted-ethane pde4 inhibitors
IL158099A0 (en)	2004-03-28	Amplifier
AU2003302588A1 (en)	2004-06-23	Phosphodiesterase 10a inhibitors
AU2003244080A1 (en)	2004-01-19	Phosphodiesterase inhibitor
AU2002303712A1 (en)	2002-11-25	Novel telomerase inhibitors and uses therefor
GB0101784D0 (en)	2001-03-07	Amplifier
EP1352911A4 (fr)	2007-11-28	Inhibiteurs de l'enzyme de conversion de l'angiotensine
GB0109278D0 (en)	2001-05-30	Enzyme inhibitors
GB0001565D0 (en)	2000-03-15	Dihydrofolate reductase inhibitors
GB2381977B (en)	2005-03-30	Amplifiers
GB0110854D0 (en)	2002-03-27	Amplifier
GB0116458D0 (en)	2001-08-29	Amplifier
GB0120882D0 (en)	2001-10-17	Amplifier
GB0104691D0 (en)	2001-04-11	Enzyme inhibitor
GB0109145D0 (en)	2001-05-30	Enzyme inhibitors
GB0102018D0 (en)	2001-03-14	Enzyme inhibitors
GB0101537D0 (en)	2001-03-07	Enzyme inhibitors
GB0102194D0 (en)	2001-03-14	Enzyme inhibitors
GB0106564D0 (en)	2001-05-09	Enzyme inhibitors